Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, on 5 march presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063. Verastem Inc. (NASDAQ:VSTM) shares after opening at $8.40 moved to $8.40 on last trade day and at the end of the day closed at $7.84. Company price to cash ratio as 2.00. Verastem Inc. (NASDAQ:VSTM) showed a negative weekly performance of -11.81%.
Genomic Health, Inc. (NASDAQ:GHDX) on 22 April announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX® breast cancer test in major German clinical guidelines. Genomic Health, Inc. (NASDAQ:GHDX) shares fell -5.03% in last trading session and ended the day on $25.13. GHDXreturn on equity ratio is recorded as -9.80% and its return on assets is -8.10%. Genomic Health, Inc. (NASDAQ:GHDX) yearly performance is -16.59%.
MediWound Ltd (NASDAQ:MDWD) had coverage initiated with an “outperform” rating by analysts at Oppenheimer. The firm set a $25 price target on the shares. Mediwound Ltd (NASDAQ:MDWD) shares moved down -5.78% in last trading session and was closed at $10.10, while trading in range of $9.85 – $10.75. Mediwound Ltd (NASDAQ:MDWD) year to date (YTD) performance is -41.52%.
IPC The Hospitalist Company, Inc. (NASDAQ:IPCM) reported Q1 EPS of $0.57, $0.07 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $172.7 million versus the consensus estimate of $183 million. IPC The Hospitalist Company Inc. (NASDAQ:IPCM) weekly performance is -13.55%. On last trading day company shares ended up $41.66. IPC The Hospitalist Company Inc. (NASDAQ:IPCM) distance from 50-day simple moving average (SMA50) is -17.65%. Analysts mean target price for the company is $56.77.
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), which went public in February, has as many as six candidates in its pipeline in addition to two approved products. The company, which raised more than $50 million from its initial public offering, intends to use the funds primarily to develop its pipeline. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares after opening at $11.47 moved to $11.59 on last trade day and at the end of the day closed at $10.23. Company price to sales ratio in past twelve months was calculated as 8.10 and price to cash ratio as 14.34. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) showed a negative weekly performance of -15.10%.